Company Vanda Pharmaceuticals Inc.

Equities

VNDA

US9216591084

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 21:00:00 04/03/2026 GMT			5-day change	1st Jan Change
8.200 ^USD	+4.59%		-0.97%	-7.03%

08:50am	Vanda Pharmaceuticals Insider Sold Shares Worth $1,276,971, According to a Recent SEC Filing	MT
03-03	Vanda Pharmaceuticals Inc. Announces FDA Grants Landmark Hearing for HETLIOZin Jet Lag Disorder	CI

Business description: Vanda Pharmaceuticals Inc.

Vanda Pharmaceuticals Inc. is a biopharmaceutical company, which is focused on the development and commercialization of therapies to address high unmet medical needs and improve the lives of patients. The Companyâ€™s commercial portfolio is comprised of three products: HETLIOZ for the treatment of non-24-hour sleep-wake disorder (Non-24) and for the treatment of nighttime sleep disturbances in smith-magenis syndrome (SMS), Fanapt (iloperidone) for the treatment of bipolar I disorder and a long acting injectable (LAI) formulation for the treatment of schizophrenia, and PONVORY (ponesimod) for the treatment of inflammatory/autoimmune disorders, including ulcerative colitis, psoriasis, Crohn's disease, atopic dermatitis, eosinophilic esophagitis and alopecia areata. The Company also has a range of drugs in development, including Tradipitant (VLY-686), VHX-896, VSJ-110, VPO-227, VTR-297, VQW-765, VCA-894A and Type 2S (CMT2S).

Number of employees: 533

Sales by Activity: Vanda Pharmaceuticals Inc.

Fiscal Period: December	2021 (USD)	2022 (USD)	2023 (USD)	2024 (USD)	2025 (USD)
Biotechnology (Startups)	269M	254M	193M	199M	216M

See all business segments

Geographical breakdown of sales: Vanda Pharmaceuticals Inc.

Fiscal Period: December	2021 (USD)	2022 (USD)	2023 (USD)	2024 (USD)	2025 (USD)
United States	269M	254M	193M	199M	216M

See all geographic segments

Executive Committee: Vanda Pharmaceuticals Inc.

Manager	Title	Age	Since
Mihael Polymeropoulos CEO	Chief Executive Officer	66	30/04/2003
Kevin Moran DFI	Director of Finance/CFO	42	14/03/2020
Scott Howell HRO	Human Resources Officer	-	31/07/2019
Kim Wijkstrom SAM	Sales & Marketing	60	20/08/2019
Tim Williams LAW	General Counsel	50	12/08/2018

See VANDA PHARMACEUTICALS INC. governance

Composition of the Board of Directors: Vanda Pharmaceuticals Inc.

Director	Title	Age	Since
Richard Dugan BRD	Director/Board Member	84	30/11/2005
Mihael Polymeropoulos CHM	Chairman	66	31/05/2021
Stephen Mitchell BRD	Director/Board Member	74	13/02/2020
Anne Ward BRD	Director/Board Member	54	27/10/2019
Phaedra Chrousos BRD	Director/Board Member	46	23/04/2019
Tage Honoré BRD	Director/Board Member	75	14/03/2023

Composition of the Board of Directors

Shareholders: Vanda Pharmaceuticals Inc.

Name	Equities	%	Valuation
BlackRock Advisors LLC 11.89 %	7,023,642	11.89 %	53 M $
Vanguard Fiduciary Trust Co. 6.315 %	3,731,851	6.315 %	28 M $
Renaissance Technologies LLC 5.721 %	3,380,961	5.721 %	25 M $
Mihael Polymeropoulos 4.841 %	2,860,731	4.841 %	22 M $
Acadian Asset Management LLC 4.079 %	2,410,414	4.079 %	18 M $

List of VANDA PHARMACEUTICALS INC. shareholders

Company details: Vanda Pharmaceuticals Inc.

Vanda Pharmaceuticals, Inc.

2200 Pennsylvania Avenue NW

20037, Washington

+202 734 3400

http://www.vandapharma.com

address Vanda Pharmaceuticals Inc.(VNDA)

Bio Therapeutic Drugs

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5d. change	1-year change	3-years change	Capi.($)
VANDA PHARMACEUTICALS INC.	+4.59%	-0.97%	+70.48%	+28.73%	485M
ARGENX SE	+0.78%	-0.74%	+9.29%	+101.24%	45.72B
WUXI APPTEC CO., LTD.	-1.85%	-7.84%	+52.40%	+10.53%	39.82B
INSMED INCORPORATED	+1.96%	+0.85%	+94.12%	+627.57%	32.31B
BIONTECH SE	+3.02%	-5.50%	-5.34%	-20.62%	26.05B
WUXI BIOLOGICS (CAYMAN) INC.	+0.40%	-7.42%	+53.42%	-38.10%	18.68B
GENMAB A/S	+0.99%	-1.55%	+9.16%	-29.32%	17.17B
AKESO, INC.	+7.03%	+0.10%	+38.87%	+134.75%	11.23B
SUMMIT THERAPEUTICS INC.	+1.79%	-1.91%	-19.43%	+898.70%	11.93B
EXELIXIS, INC.	+2.33%	-6.84%	+8.88%	+143.09%	10.83B
Average	+2.10%	-5.64%	+31.18%	+185.66%	21.42B
Weighted average by Cap.	+1.19%	-6.12%	+32.23%	+174.43%